OOIR: Observatory of International Research

Papers

(The H4-Index of European Respiratory Journal is 62. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Tricuspid regurgitation in pulmonary arterial hypertension: a right ventricular volumetric and functional analysis	980
The right ventricle tamed	706
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target	600
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis	355
Fibroblast heterogeneity in pulmonary fibrosis: a new target for therapeutics development?	325
Similarity network fusion for the integration of multi-omics and microbiomes in respiratory disease	232
Chymase-1: a “MAST”-er switch in COPD?	196
Salivary polyreactive antibodies andHaemophilus influenzaeare associated with respiratory infection severity in young children with recurrent respiratory infections	191
The Cochrane review of electronic cigarettes for smoking cessation: remaining focused on the evidence	155
If your patient with asthma wheezes when sitting or lying quietly, lung function testing may reveal small airway disease	149
Missing airways, ventilation defects and conductive airway physiology in asthma	144
Epigenome-wide association studies: the exposures of yesterday form the methylations of tomorrow	137
Moving the needle on proteasome inhibitor-induced pulmonary arterial hypertension: a definite maybe	137
Natural decline in pulmonary function following bilateral lung transplantation: a single-centre study	125
A breath of the future: a novel human model for COPD and beyond	118
Randomised controlled trials utilisingF_ENOto manage asthma: is it time to acknowledge that “one size does not fit all”?	118
The lung that rules the heart	118
Prenatal exposure to greenness and early childhood pneumonia: a nationwide study in Japan	114
Repositioning of ezetimibe for the treatment of idiopathic pulmonary fibrosis	114
Plasma cells: a feasible therapeutic target in pulmonary fibrosis?	113
The NIVO score: can it help to improve noninvasive ventilation in daily clinical practice?	111
“The Noninvasive Ventilation Outcomes (NIVO) score: prediction of in-hospital mortality in exacerbations of COPD requiring assisted ventilation.” Tom Hartley, Nicholas D. Lane, John Steer,et al	106
Collaboration between explainable artificial intelligence and pulmonologists improves the accuracy of pulmonary function test interpretation	105
Mortality trends in pulmonary arterial hypertension in Canada: a temporal analysis of survival per ESC/ERS guideline era	105
Arousal threshold modifies the effect of CPAP on executive function among individuals with obstructive sleep apnoea	104

Revisiting asthma pharmacotherapy: where do we stand and where do we want to go?	96
RIPK1 kinase-dependent inflammation and cell death contribute to the pathogenesis of COPD	91
Antiviral CD8⁺T-cell immune responses are impaired by cigarette smoke and in COPD	90
Characterisation of paediatric pulmonary hypertensive vascular disease from the PPHNet Registry	87
The novel bronchodilator navafenterol: a phase 2a, multicentre, randomised, double-blind, placebo-controlled crossover trial in COPD	87
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial	86
Circulating anti-nuclear autoantibodies in COVID-19 survivors predict long-COVID symptoms	85
Socioeconomic biases in asthma control and specialist referral of possible severe asthma	81
Long-term radiological and pulmonary function abnormalities at 3 years after COVID-19 hospitalisation: a longitudinal cohort study	80
Pleural fluid proteomics from patients with pleural infection shows signatures of diverse neutrophilic responses: The Oxford Pleural Infection Endotyping Study (TORPIDS-2)	79
A patient-tailored approach for corticosteroid treatment in COVID-19: still not there yet	78
Invisibility of breathlessness in clinical consultations: a cross-sectional, national online survey	77
The environmental impact of inhaled therapy: making informed treatment choices	77
A systematic review of blood biomarkers with individual participant data meta-analysis of matrix metalloproteinase-7 in idiopathic pulmonary fibrosis	77
Cystic fibrosis macrophage function and clinical outcomes after elexacaftor/tezacaftor/ivacaftor	76
Epidemiological cut-off values for a 96-well broth microdilution plate for high-throughput research antibiotic susceptibility testing ofM. tuberculosis	76
Idiopathic pleuroparenchymal fibroelastosis: three-dimensional computed tomography assessment of upper-lobe lung volume	75
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection	75
Treatment algorithm for pulmonary arterial hypertension	74
Combining rituximab with mycophenolate for the treatment of interstitial lung disease	73
Associations of hiatus hernia with CT-based interstitial lung changes: the MESA Lung Study	72
Genomic classifier for usual interstitial pneumonia combined with bronchoalveolar lavage cellular profile: potential use in the clinical management of new onset ILD?	72
Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension	72
The association between immunosuppressants and outcomes of COVID-19	71
Inhaled recombinant GM-CSF reduces the need for whole lung lavage and improves gas exchange in autoimmune pulmonary alveolar proteinosis patients	71
Impact of hepatopulmonary syndrome in liver transplantation candidates and the role of angiogenesis	71
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain	70
Nasopharyngeal metatranscriptome profiles of infants with bronchiolitis and risk of childhood asthma: a multicentre prospective study	70
Real-world monitoring of elexacaftor-tezacaftor-ivacaftor trough concentrations in adults with cystic fibrosis	69
Vitamin D deficiency, a potential cause for insufficient response to sildenafil in pulmonary arterial hypertension	69
Lunsekimig's bispecific targeting of IL-13 and TSLP in asthma: dual targets for synergistic effects?	69
Intracellular hydroxyproline imprinting following resolution of bleomycin-induced pulmonary fibrosis	69
The limits of normal of pulmonary arterial wedge pressure	68
Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?	67
Reply: Tuberculosis screening in migrants to the EU/EEA and UK	66
Clean air for healthy lungs – an urgent call to action: European Respiratory Society position on the launch of the WHO 2021 Air Quality Guidelines	65
Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough	65
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19	62